Genmab Announces Update on Zalutumumab

Summary:  Genmab provides an update on the potential regulatory pathway for     
zalutumumab.                                                                    

- Genmab has received preliminary feedback from selected national European      
regulatory authorities and FDA on zalutumumab                                   
- Genmab believes a MAA for zalutumumab in second line head and neck cancer     
could be pursued based on available clinical data                               
- Additional clinical study data would be required prior to a US regulatory     
submission                                                                      

Copenhagen, Denmark; October 18, 2010 - Genmab A/S (OMX: GEN) announced today an
update on the potential regulatory pathway for zalutumumab following            
preliminary, non-binding discussions with a number of selected national European
regulatory authorities and the FDA.  Based on overall feedback from regulatory  
authorities in Europe, Genmab believes a Marketing Authorization Application    
(MAA) for zalutumumab could be pursued based on the data from the Phase III     
study in patients with recurrent or metastatic squamous cell carcinoma of the   
head and neck (SCCHN) who failed standard platinum-based therapy, reported      
earlier this year. Additional clinical study data would, however, be required   
prior to submitting a regulatory application in the US.                         

“Our discussions with the regulatory authorities have been very productive and  
we are encouraged by the overall feedback we have received,” said Prof. Jan van 
de Winkel, Ph.D., Chief Executive Officer of Genmab.  “We are advancing our     
partnership discussions in earnest and feel confident that our potential future 
development partner would be able to move forward with a European regulatory    
filing for zalutumumab.”                                                        

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for the potential treatment of cancer.        
Genmab's world class discovery and development teams are using cutting-edge     
technology to create and develop products to address unmet medical needs.  Our  
primary goal is to improve the lives of patients who are in urgent need of new  
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

This Stock Exchange Release contains forward looking statements. The words      
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions  
identify forward looking statements. Actual results or performance may differ   
materially from any future results or performance expressed or implied by such  
statements. The important factors that could cause our actual results or        
performance to differ materially include, among others, risks associated with   
product discovery and development, uncertainties related to the outcome and     
conduct of clinical trials including unforeseen safety issues, uncertainties    
related to product manufacturing, the lack of market acceptance of our products,
our inability to manage growth, the competitive environment in relation to our  
business area and markets, our inability to attract and retain suitably         
qualified personnel, the unenforceability or lack of protection of our patents  
and proprietary rights, our relationships with affiliated entities, changes and 
developments in technology which may render our products obsolete, and other    
factors. For a further discussion of these risks, please refer to the section   
“Risk Management” in Genmab's Annual Report, which is available on              
www.genmab.com.  Genmab does not undertake any obligation to update or revise   
forward looking statements in this Stock Exchange Release nor to confirm such   
statements in relation to actual results, unless required by law.               

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-TF(TM);     
HuMax-Her2(TM); HuMax-Wnt(TM); HuMax-cMet(TM) and UniBody(R) are all trademarks 
of Genmab A/S. Arzerra(R) is a trademark of GlaxoSmithKline.                    

Contact: Helle Husted, Vice President, Investor Relations, T: +45 33 44 77 30,  
M: +45 25 27 47 13, E: h.husted@genmab.com                                      
                                                                                
Stock Exchange Release no. 40/2010                                              

###